World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
33884
World Ranking
10453
National Ranking
1001

John F.R. Robertson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John F.R. Robertson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 386 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John F.R. Robertson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John F.R. Robertson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John F.R. Robertson is affiliated with the University of Nottingham in the United Kingdom. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, contributing notably to the areas of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Surgery.

Their work focuses on several key topics including:

  • Estrogen and related hormone effects
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Global Cancer Incidence and Screening
  • Cancer Treatment and Pharmacology
  • Cancer survivorship and care

Among recent publications, the following papers reflect some of the contributions made:

  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials" (2021), published in The Lancet Oncology
  • "Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial" (2020), published in The Lancet Oncology
  • "ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials" (2020), published in Clinical Cancer Research
  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials" (2023), published in The Lancet
  • "Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic" (2020), published in npj Breast Cancer

Frequently collaborating with other researchers, John F.R. Robertson has co-authored numerous works alongside:

  • Judith M. Bliss
  • Mitch Dowsett
  • Lucy Kilburn
  • Holly Tovey
  • Maggie C.U. Cheang

Their publications have appeared consistently in various scientific venues, with multiple contributions to:

  • Cancer Research
  • European Journal of Surgical Oncology
  • Clinical Cancer Research
  • The Lancet
  • BMJ Open Quality

Best Publications

  • Prognostic markers in triple-negative breast cancer

    Emad A. Rakha;Maysa E. El-Sayed;Andrew R. Green;Andrew H. S. Lee

  • Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

    J Bonneterre;B Thurlimann;J Robertson;M Krzakowski

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

    Anthony Howell;John F R Robertson;J Quaresma Albano;A Aschermannova

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

    Dalia M. Abd El-Rehim;Graham Ball;Sarah E. Pinder;Emad Rakha

  • Expression of luminal and basal cytokeratins in human breast carcinoma

    Dalia M Abd El-Rehim;Sarah E Pinder;Claire E Paish;J Bell

  • Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

    Jacques Bonneterre;Aman Buzdar;Jean‐Marc A. Nabholtz;John F. R. Robertson

  • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

    Stephen Chia;William Gradishar;Louis Mauriac;Jose Bines

  • Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

    John F.R. Robertson;Igor M. Bondarenko;Ekaterina Trishkina;Mikhail Dvorkin

  • Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

    Anthony Howell;John F R Robertson;Paul Abram;Mikhail R Lichinitser

  • Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

    Anthony Howell;John Robertson

  • Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

    E A Rakha;T C Putti;D M Abd El-Rehim;C Paish

  • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.

    John F.R. Robertson;C. Kent Osborne;Anthony Howell;Stephen E. Jones

  • Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive Phenotype

    Emad A. Rakha;Maysa E. El-Sayed;Andrew R. Green;E. Claire Paish

  • Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

    Emad A Rakha;Richard W G Boyce;Dalia Abd El-Rehim;Thomas Kurien

  • Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer

    Julia Margaret Wendy Gee;J. F. Robertson;E. Gutteridge;I. O. Ellis

  • Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

    John F.R. Robertson;Antonio Llombart-Cussac;Janusz Rolski;David Feltl

  • Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

    N. Bouzubar;K. J. Walker;K. Griffiths;I. O. Ellis

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

Frequent Co-Authors

Ian O. Ellis
Ian O. Ellis University of Nottingham
Robert Ian Nicholson
Robert Ian Nicholson Cardiff University
Roger W. Blamey
Roger W. Blamey Nottingham City Hospital
Julia Margaret Wendy Gee
Julia Margaret Wendy Gee Cardiff University
Sarah E Pinder
Sarah E Pinder King's College London
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Anthony Howell
Anthony Howell University of Manchester
C.W. Elston
C.W. Elston University of Nottingham
Matthew J. Ellis
Matthew J. Ellis Baylor College of Medicine
Andrew Evans
Andrew Evans University of Dundee

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine goes beyond becoming a doctor. The healthcare field in the U.S. offers a variety of related degree options and career pathways, many of which can be pursued online for added flexibility. For those interested in nursing, some nursing schools that don't require teas test can provide a more accessible route into the nursing profession.

If you are more interested in management or organizational roles, consider an online healthcare administration degree. This can open doors to leadership positions in hospitals, clinics, and public health organizations.

RNs looking to advance their careers may benefit from adn to np programs online, which provide flexible bridge programs to help nurses become nurse practitioners faster. Additionally, those passionate about wellness and nutrition can earn an online bs in nutrition to explore roles in dietetics, health coaching, and education.

Exploring these related online degrees can help you tailor a healthcare career that fits your strengths and interests, all while balancing work and study commitments.

Best Scientists Citing John F.R. Robertson

Trending Scientists

Recently Published Articles